Beam Therapeutics (BEAM)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Base Editingsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-12. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 16/100 (LOW), 31.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 31.31% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
- Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
- Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative
- Beam sues 2 biotechs, alleging theft of base editing trade secrets
- As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock
- Anthropic AI Discovery Gene-Editing Stocks Falling
- Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows
- Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Beam Therapeutics.
Full BEAM Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.